RUBIN PAUL D 4
4 · BioAge Labs, Inc. · Filed Jan 6, 2026
Insider Transaction Report
Form 4
RUBIN PAUL D
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2026-01-02$4.11/sh+5,433$22,330→ 5,433 total - Exercise/Conversion
Common Stock
2026-01-02$6.57/sh+2,000$13,140→ 7,433 total - Sale
Common Stock
2026-01-02$12.85/sh−7,433$95,490→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2026-01-02−5,433→ 16,303 totalExercise: $4.11Exp: 2030-06-30→ Common Stock (5,433 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2026-01-02−2,000→ 7,383 totalExercise: $6.57Exp: 2032-05-28→ Common Stock (2,000 underlying)
Footnotes (4)
- [F1]The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.571 to $13.242 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024.
- [F4]The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.